Content deleted Content added
m category |
no longer a stub |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 1:
{{
{{Use American English|date=February 2021}}
{{Use dmy dates|date=February 2021}}
{{Infobox drug
| image = Trilaciclib.svg
| width =
Line 16 ⟶ 13:
| Drugs.com = {{drugs.com|pro|Cosela}}
| MedlinePlus =
| DailyMedID = Trilaciclib
| pregnancy_
| pregnancy_
| pregnancy_category=
| routes_of_administration = [[Intravenous]]
| class = [[CDK inhibitor|Cyclin-dependent kinase (CDK) inhibitor]]
| ATC_prefix = V03
| ATC_suffix = AF12
Line 124 ⟶ 116:
== External links ==
* {{ClinicalTrialsGov|NCT03041311|Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02499770|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)}}
* {{ClinicalTrialsGov|NCT02514447|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy}}
{{Detoxifying agents for antineoplastic treatment}}
{{Portal bar | Medicine}}
[[Category:Protein kinase inhibitors]]
[[Category:Chemotherapeutic adjuvants]]
Line 141 ⟶ 131:
[[Category:Guanidines]]
[[Category:CDK inhibitors]]
|